Advertisement

Archivum Immunologiae et Therapiae Experimentalis

, Volume 66, Issue 6, pp 431–442 | Cite as

Precision/Personalized Medicine in Allergic Diseases and Asthma

  • Umut Can Kucuksezer
  • Cevdet Ozdemir
  • Mubeccel Akdis
  • Cezmi A. AkdisEmail author
Review
  • 384 Downloads

Abstract

Like many other chronic diseases, every allergic patient has different characteristics based on clinical course, treatment responsiveness and disease outcomes, which are associated with the genetic and epigenetic control of molecular mechanisms and environment. This variability necessitates the establishment of patient-tailored and precision approaches in handling allergic disorders. Better understanding of the underlying pathophysiological mechanisms for the development of allergic disorders will provide more rationale strategies based on individual cases in controlling and treating these disorders. Endotyping, phenotyping, genotyping and theratyping, and biomarkers are keywords in this area and have been gaining lots of attention in the field of precision medicine, which aims to revolutionize patient care and develop better prevention and treatment strategies. In addition, precision health is a new concept that brings precise approaches to the scene for being healthy and prevention of allergic disease and asthma. The specialty of allergy has a leading role in the field, because allergen-specific immunotherapy started 105 years ago, and is historically a leading personalized/precision medicine approach in all medicine disciplines providing the possibility of cure in an individualized manner instead of conventional symptomatic treatments.

Keywords

Allergy Asthma Biomarker Endotype Phenotype Theratype Genotype Cytokines Precision medicine Personalized medicine 

Abbreviations

AIT

Allergen-specific immunotherapy

Breg

B regulatory

DC

Dendritic cells

Ig

Immunoglobulin

IL

Interleukin

ILC

Innate lymphoid cells

miRNA

MicroRNA

NK

Natural killer

SCIT

Subcutaneous immunotherapy

SLIT

Sublingual immunotherapy

Th

T helper

Treg

T regulatory

Notes

Acknowledgements

The authors’ lab has been supported by Swiss National Science Foundation and Christine Kühne—Center for Allergy Research and Education.

Compliance with Ethical Standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. Agache I (2018) EAACI guidelines on allergen immunotherapy-Out with the old and in with the new. Allergy 73:737–738PubMedGoogle Scholar
  2. Agache I, Akdis CA (2016) Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int 65:243–252PubMedGoogle Scholar
  3. Agache I, Akdis C, Jutel M et al (2012) Untangling asthma phenotypes and endotypes. Allergy 67:835–846PubMedGoogle Scholar
  4. Agache I, Sugita K, Morita H et al (2015) The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep 15:29PubMedGoogle Scholar
  5. Akdis CA, Akdis M (2014a) Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest 124:4678–4680PubMedPubMedCentralGoogle Scholar
  6. Akdis M, Akdis CA (2014b) Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 133:621–631PubMedGoogle Scholar
  7. Akdis CA, Akdis M (2015) Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med 7:280ps286Google Scholar
  8. Akdis CA, Ballas ZK (2016) Precision medicine and precision health: building blocks to foster a revolutionary health care model. J Allergy Clin Immunol 137:1359–1361PubMedGoogle Scholar
  9. Akdis M, Verhagen J, Taylor A et al (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199:1567–1575PubMedPubMedCentralGoogle Scholar
  10. Akdis CA, Bachert C, Cingi C et al (2013) Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 131:1479–1490PubMedPubMedCentralGoogle Scholar
  11. Akdis M, Aab A, Altunbulakli C et al (2016) Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 138:984–1010Google Scholar
  12. Anderson WC 3rd, Szefler SJ (2015) New and future strategies to improve asthma control in children. J Allergy Clin Immunol 136:848–859PubMedGoogle Scholar
  13. Annunziato F, Romagnani C, Romagnani S (2015) The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 135:626–635PubMedGoogle Scholar
  14. Arm JP, Bottoli I, Skerjanec A et al (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44:1371–1385PubMedPubMedCentralGoogle Scholar
  15. Bachert C, Akdis CA (2016) Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract 4:621–628PubMedGoogle Scholar
  16. Baird B, Shopes RJ, Oi VT et al (1989) Interaction of IgE with its high-affinity receptor. Structural basis and requirements for effective cross-linking. Int Arch Allergy Appl Immunol 88:23–28PubMedGoogle Scholar
  17. Beck LA, Thaçi D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139PubMedGoogle Scholar
  18. Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197PubMedGoogle Scholar
  19. Berry A, Busse WW (2016) Biomarkers in asthmatic patients: Has their time come to direct treatment? J Allergy Clin Immunol 137:1317–1324PubMedGoogle Scholar
  20. Bhutani M, Yang WH, Hebert J et al (2017) The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS One 12:e0183869PubMedPubMedCentralGoogle Scholar
  21. Bieber T, Vieths S, Broich K (2016) New opportunities and challenges in the assessment of drugs for atopic diseases. Allergy 71:1662–1665PubMedGoogle Scholar
  22. Bleecker ER, FitzGerald JM, Chanez P et al (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115–2127PubMedGoogle Scholar
  23. Bonertz A, Roberts G, Slater JE et al (2018) Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: an analysis from the EAACI AIT Guidelines Project. Allergy 73:816–826PubMedGoogle Scholar
  24. Boonpiyathad T, Meyer N, Moniuszko M et al (2017) High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. Allergy 72:407–415PubMedGoogle Scholar
  25. Bousquet J, Schünemann HJ, Samolinski B et al (2012) Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 130:1049–1062PubMedGoogle Scholar
  26. Busse WW, Morgan WJ, Gergen PJ et al (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364:1005–1015PubMedPubMedCentralGoogle Scholar
  27. Castro M, Wenzel SE, Bleecker ER et al (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:879–890PubMedGoogle Scholar
  28. Castro M, Zangrilli J, Wechsler ME et al (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355–366PubMedGoogle Scholar
  29. Chung KF (2015) Targeting the interleukin pathway in the treatment of asthma. Lancet 386:1086–1096PubMedGoogle Scholar
  30. Chupp GL, Bradford ES, Albers FC et al (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390–400PubMedGoogle Scholar
  31. Curin M, Garmatiuk T, Resch-Marat Y et al (2018) Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE cross-reactivity. Allergy.  https://doi.org/10.1111/all.13398 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Dantzer JA, Wood RA (2018) The use of omalizumab in allergen immunotherapy. Clin Exp Allergy 48:232–240PubMedGoogle Scholar
  33. Di Bona D, Plaia A, Leto-Barone MS et al (2017) Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy 72:691–704PubMedGoogle Scholar
  34. Doherty TA, Baum R, Newbury RO et al (2015) Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis. J Allergy Clin Immunol 136:792–794 e3PubMedPubMedCentralGoogle Scholar
  35. Durham SR, Penagos M (2016) Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 137:339–349 (e10) PubMedGoogle Scholar
  36. Ferrando M, Bagnasco D, Varricchi G et al (2017) Personalized medicine in allergy. Allergy Asthma Immunol Res 9:15–24PubMedGoogle Scholar
  37. Galli SJ (2016) Toward precision medicine and health: Opportunities and challenges in allergic diseases. J Allergy Clin Immunol 137:1289–1300PubMedPubMedCentralGoogle Scholar
  38. Gauvreau GM, Harris JM, Boulet LP et al (2014) Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 6:243ra85PubMedGoogle Scholar
  39. Gueguen C, Bouley J, Moussu H et al (2016) Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol 137:545–558PubMedGoogle Scholar
  40. Haldar P, Brightling CE, Hargadon B et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973–984PubMedPubMedCentralGoogle Scholar
  41. Hoffmann HJ, Valovirta E, Pfaar O et al (2017) Novel approaches and perspectives in allergen immunotherapy. Allergy 72:1022–1034PubMedGoogle Scholar
  42. Inoue T, Akashi K, Watanabe M et al (2016) Periostin as a biomarker for the diagnosis of pediatric asthma. Pediatr Allergy Immunol 27:521–526PubMedGoogle Scholar
  43. Jackson DJ, Makrinioti H, Rana BM et al (2014) IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 190:1373–1382PubMedPubMedCentralGoogle Scholar
  44. James A, Janson C, Malinovschi A et al (2017) Serum periostin relates to type-2 inflammation and lung function in asthma: Data from the large population-based cohort Swedish GA(2)LEN. Allergy 72:1753–1760PubMedGoogle Scholar
  45. Katz SI, Parker D, Turk JL (1974) B-cell suppression of delayed hypersensitivity reactions. Nature 251:550–551PubMedGoogle Scholar
  46. Komlosi Z, Kovács N, van de Veen W et al (2017) Human CD40L-expressing type 3 innate lymphoid cells induce IL-10 producing immature transitional regulatory B cells. J Allergy Clin Immunol.  https://doi.org/10.1016/j.jaci.2017.07.046 CrossRefPubMedGoogle Scholar
  47. Konig K, Klemens C, Eder K et al (2015) Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol 11:26PubMedPubMedCentralGoogle Scholar
  48. Kouser L, Kappen J, Walton RP et al (2017) Update on biomarkers to monitor clinical efficacy response during and post treatment in allergen immunotherapy. Curr Treat Options Allergy 4:43–53PubMedPubMedCentralGoogle Scholar
  49. Kucuksezer UC, Ozdemir C, Akdis M et al (2013a) Mechanisms of immune tolerance to allergens in children. Korean J Pediatr 56:505–513PubMedPubMedCentralGoogle Scholar
  50. Kucuksezer UC, Palomares O, Rückert B et al (2013b) Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol 131:875–885PubMedGoogle Scholar
  51. Kussebi F, Karamloo F, Rhyner C et al (2005) A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 115:323–329PubMedGoogle Scholar
  52. Larche M, Akdis CA, Valenta R (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6:761–771PubMedGoogle Scholar
  53. Lawrence MG, Woodfolk JA, Schuyler AJ et al (2017) Half-life of IgE in serum and skin: consequences for anti-IgE therapy in patients with allergic disease. J Allergy Clin Immunol 139:422–428 (e4) PubMedGoogle Scholar
  54. Lee JH, Lee HY, Jung CG et al (2018) Therapeutic effect of omalizumab in severe asthma: a real-world study in Korea. Allergy Asthma Immunol Res 10:121–130PubMedPubMedCentralGoogle Scholar
  55. Lin C, Lee IT, Sampath V et al (2017) Combining anti-IgE with oral immunotherapy. Pediatr Allergy Immunol 28:619–627PubMedGoogle Scholar
  56. Liu Y, Zhang S, Li DW et al (2013) Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 8:e59872PubMedPubMedCentralGoogle Scholar
  57. Lombardi V, Beuraud C, Neukirch C et al (2016) Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects. J Allergy Clin Immunol 138:305–308PubMedGoogle Scholar
  58. Massanari M, Nelson H, Casale T et al (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125:383–389PubMedGoogle Scholar
  59. Mjosberg J, Spits H (2016) Human innate lymphoid cells. J Allergy Clin Immunol 138:1265–1276Google Scholar
  60. Morita H, Arae K, Unno H et al (2015) An Interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43:175–186PubMedPubMedCentralGoogle Scholar
  61. Muehling LM, Lawrence MG, Woodfolk JA (2017) Pathogenic CD4 + T cells in patients with asthma. J Allergy Clin Immunol 140:1523–1540PubMedGoogle Scholar
  62. Muraro A, Lemanske RF Jr, Hellings PW et al (2016) Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 137:1347–1358PubMedGoogle Scholar
  63. Muraro A, Lemanske RF Jr, Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021PubMedGoogle Scholar
  64. Nagakumar P, Denney L, Fleming L et al (2016) Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J Allergy Clin Immunol 137:624–626 (e6) PubMedGoogle Scholar
  65. Nagarkar DR, Ramirez-Carrozzi V, Choy DF et al (2015) IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells. J Allergy Clin Immunol 136:202–205PubMedGoogle Scholar
  66. Nair P, Wenzel S, Rabe KF et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448–2458PubMedGoogle Scholar
  67. Neta R, Salvin SB (1974) Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol 113:1716–1725PubMedGoogle Scholar
  68. Normansell R, Walker S, Milan SJ et al (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev (1):CD003559Google Scholar
  69. O’Byrne PM, Inman MD, Parameswaran K (2001) The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 108:503–508PubMedGoogle Scholar
  70. O’Mahony L, Akdis CA, Eiwegger T (2016) Innate mechanisms can predict successful allergy immunotherapy. J Allergy Clin Immunol 137:559–561PubMedGoogle Scholar
  71. Oettgen HC (2016) Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol 137:1631–1645PubMedPubMedCentralGoogle Scholar
  72. Ozdemir C (2009) Monoclonal antibodies in allergy; current applications and promising trials. Recent Pat Inflamm Allergy Drug Discov 3:201–210PubMedGoogle Scholar
  73. Ozdemir C (2015) Monoclonal antibodies in allergy; updated applications and promising trials. Recent Pat Inflamm Allergy Drug Discov 9:54–65PubMedGoogle Scholar
  74. Ozdemir C, Kucuksezer UC, Akdis M et al (2011) Specific immunotherapy and turning off the T cell: how does it work? Ann Allergy Asthma Immunol 107:381–392PubMedGoogle Scholar
  75. Ozdemir C, Kucuksezer UC, Akdis M et al (2016) Mechanisms of aeroallergen immunotherapy: subcutaneous immunotherapy and sublingual immunotherapy. Immunol Allergy Clin North Am 36:71–86PubMedGoogle Scholar
  76. Ozyigit LP, Morita H, Akdis M (2015) Erratum to: Innate lymphoid cells in asthma phenotypes. Clin Transl Allergy 5:32PubMedPubMedCentralGoogle Scholar
  77. Palomares O, Martin-Fontecha M, Lauener R et al (2014) Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta. Genes Immun 15:511–520PubMedGoogle Scholar
  78. Pavord ID, Korn S, Howarth P et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659PubMedGoogle Scholar
  79. Pfaar O, Bonini S, Cardona V et al (2018) Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 73 Suppl 104:5–23Google Scholar
  80. Platts-Mills TA, Schuyler AJ, Erwin EA et al (2016) IgE in the diagnosis and treatment of allergic disease. J Allergy Clin Immunol 137:1662–1670PubMedPubMedCentralGoogle Scholar
  81. Pohlit H, Bellinghausen I, Frey H et al (2017) Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy 72:1461–1474PubMedGoogle Scholar
  82. Rebane A, Akdis CA (2013) MicroRNAs: Essential players in the regulation of inflammation. J Allergy Clin Immunol 132:15–26PubMedGoogle Scholar
  83. Rebane A, Runnel T, Aab A et al (2014) MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol 134:836–847 (e11) PubMedGoogle Scholar
  84. Roberts G, Pfaar O, Akdis CA et al (2018) EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy 73:765–798PubMedPubMedCentralGoogle Scholar
  85. Rodrigo GJ, Neffen H (2015) Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 26:551–556PubMedGoogle Scholar
  86. Salimi M, Barlow JL, Saunders SP et al (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210:2939–2950PubMedPubMedCentralGoogle Scholar
  87. Schulze J, Rose M, Zielen S (2007) Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 62:963–964PubMedGoogle Scholar
  88. Shimoda T, Odajima H, Okamasa A et al (2017) Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol Int 66:445–451PubMedGoogle Scholar
  89. Shin JU, Kim SH, Noh JY et al (2018) Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model. Allergy.  https://doi.org/10.1111/all.13465 CrossRefPubMedGoogle Scholar
  90. Sirvent S, Soria I, Cirauqui C et al (2016) Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol 138:558–567 (e11) PubMedGoogle Scholar
  91. Smaldini PL, Trejo F, Cohen JL et al (2018) Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells. Allergy 73:885–895PubMedGoogle Scholar
  92. Soria I, López-Relaño J, Viñuela M et al (2018) Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Allergy 73:875–884PubMedPubMedCentralGoogle Scholar
  93. Sorkness CA, Wildfire JJ, Calatroni A et al (2013) Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract 1:163–171PubMedPubMedCentralGoogle Scholar
  94. Stanic B, van de Veen W, Wirz OF et al (2015) IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol 135:771–780 (e8) PubMedGoogle Scholar
  95. Su MW, Lin WC, Tsai CH et al (2018) Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression. Allergy.  https://doi.org/10.1111/all.13439 CrossRefPubMedGoogle Scholar
  96. Tabatabaian F, Casale TB (2015) Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). Allergy Asthma Proc 36:100–104PubMedGoogle Scholar
  97. Takahashi K, Meguro K, Kawashima H et al (2018) Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma.  https://doi.org/10.1080/02770903.2018.1455855 CrossRefPubMedGoogle Scholar
  98. van de Veen W, Stanic B, Wirz OF et al (2016) Role of regulatory B cells in immune tolerance to allergens and beyond. J Allergy Clin Immunol 138:654–665PubMedGoogle Scholar
  99. Wang FP, Liu T, Lan Z et al (2016) Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One 11:e0166833PubMedPubMedCentralGoogle Scholar
  100. Werfel T, Allam JP, Biedermann T et al (2016) Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 138:336–349PubMedGoogle Scholar
  101. Wills-Karp M, Luyimbazi J, Xu X et al (1998) Interleukin-13: central mediator of allergic asthma. Science 282:2258–2261PubMedGoogle Scholar
  102. Wolf M, Twaroch TE, Huber S et al (2017) Amb a 1 isoforms: unequal siblings with distinct immunological features. Allergy 72:1874–1882PubMedPubMedCentralGoogle Scholar
  103. Yii AC, Tay TR, Choo XN et al (2018) Precision medicine in united airways disease: a “treatable traits” approach. Allergy.  https://doi.org/10.1111/all.13496 CrossRefPubMedGoogle Scholar
  104. Zaleska A, Eiwegger T, Soyer O et al (2014) Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy 69:1162–1170PubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2018

Authors and Affiliations

  1. 1.Department of Immunology, Aziz Sancar Institute of Experimental MedicineIstanbul UniversityIstanbulTurkey
  2. 2.Department of Pediatric Basic Sciences, Institute of Child HealthIstanbul UniversityIstanbulTurkey
  3. 3.Swiss Institute of Allergy and Asthma ResearchUniversity of ZurichDavosSwitzerland
  4. 4.Christine Kühne-Center for Allergy Research and Education (CK-CARE)DavosSwitzerland

Personalised recommendations